Schütz Viktoria, Geisler Christine, Rath Mathias, Böning Sarah, Treber Thomas, Stenzinger Albrecht, Brobeil Alexander, Reinhard Oliver, Duensing Anette, Duensing Stefan, Hohenfellner Markus, Görtz Magdalena
Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Front Digit Health. 2025 Mar 27;7:1530321. doi: 10.3389/fdgth.2025.1530321. eCollection 2025.
Prospective data registration is the basis of clinical oncological research. Commonly, case documentation is restricted to studies investigating a defined hypothesis. Only few institutions prospectively register all oncological patients with a reliable, sustainable and continuous follow-up infrastructure. The Department of Urology of the Heidelberg University Hospital started its prospective tumor data base in 1992. Since then, the clinical course of all oncological in-patients is continuously registered within a life-long follow-up (success rate: 93%). Associated tumor tissue is stored in the Heidelberg Biobank. In 2005, the transfer of this invaluable registry from the initial InterSystemsCache®/KRAZTUR system to a modern data warehouse was initiated. However, the transfer of existing data into a new environment proved to be technically challenging.
To migrate the existing data into a modern data warehouse (DATA 5.0) while maintaining data extraction functions. Additional requirements included FHIR connectivity, big data analyses and AI applications.
Together with SAP SE, DATA 5.0 was developed. Based on SAP HANA® (High Performance Analytic Appliance) it allows data registration and analysis with third party analytical tools. The project was supported by members of the SAP SE executive board and funded by the Dietmar Hopp Foundation.
Data Acquisition, Translation & Analysis 5.0 (DATA 5.0), a web-based tool for data registration, preservation and analysis of treatment and follow-up data, was developed to proof-of-concept stage. DATA 5.0 was then implemented into clinical practice replacing the previous system. As of today, 15,345 oncological patients and 6.7 Mio. data points are registered.
Prospective long-term data was successfully migrated into DATA 5.0, allowing data preservation, flexibility and capabilities for future data sources. DATA 5.0, together with associated tumor tissue, is a lighthouse platform for oncological research, with capability for third party analytical tools, big data analysis and AI applications including training of digital twin models.
前瞻性数据登记是临床肿瘤学研究的基础。通常情况下,病例记录仅限于针对特定假设进行研究的项目。只有少数机构会前瞻性地登记所有肿瘤患者,并建立可靠、可持续且持续的随访基础设施。海德堡大学医院泌尿外科于1992年启动了前瞻性肿瘤数据库。从那时起,所有肿瘤住院患者的临床病程都在终身随访中持续登记(成功率:93%)。相关肿瘤组织存储在海德堡生物样本库中。2005年,该宝贵的登记系统从最初的InterSystemsCache®/KRAZTUR系统迁移至现代数据仓库。然而,将现有数据迁移到新环境在技术上具有挑战性。
将现有数据迁移到现代数据仓库(DATA 5.0),同时保留数据提取功能。其他要求包括FHIR连接性、大数据分析和人工智能应用。
与思爱普公司(SAP SE)合作开发了DATA 5.0。它基于思爱普HANA®(高性能分析设备),允许使用第三方分析工具进行数据登记和分析。该项目得到了思爱普公司执行董事会成员的支持,并由迪特马尔·霍普基金会资助。
数据采集、转换与分析5.0(DATA 5.0)这一基于网络的工具,用于治疗和随访数据的登记、保存及分析,已开发至概念验证阶段。随后,DATA 5.0在临床实践中得以实施,取代了先前的系统。截至目前,已登记了15345名肿瘤患者和670万个数据点。
前瞻性长期数据已成功迁移至DATA 5.0,为未来数据源提供了数据保存、灵活性及功能。DATA 5.0连同相关肿瘤组织,是肿瘤学研究的灯塔平台,具备使用第三方分析工具、进行大数据分析和人工智能应用(包括数字孪生模型训练)的能力。